AUNA Q1 Preview: Flat EPS, Mexico Weakness Keep WAIT Rating Intact

What happened

AUNA heads into its May 19 Q1 earnings report with expectations of flat EPS and 8%+ revenue growth, but weak signals from Mexico continue to cloud the outlook. The DeepValue master report maintains a WAIT rating, emphasizing that the stock's $5.20 price offers no margin of safety given tight covenant headroom and a reliance on Mexico volume recovery. Mexico bed utilization fell to 38.6% in FY25 from 42.4%, and 1Q26 KPIs showed utilization and emergency treatments still down year-over-year. Management's FY26 guidance of ~10-14% FX-neutral revenue and EBITDA growth hinges on Mexico turning around through contracted payer tier wins and ISSSTELEON repricing, yet evidence of inflection is absent. The next key catalyst is the Q1 print, which must show stabilization in Mexico operating metrics to avoid further compression in covenant headroom.

Implication

The Q1 earnings report is unlikely to provide the step change needed to justify buying today, as EPS is expected flat and Mexico's top line may still lag. Without a clear uptick in Mexico emergency visits and bed utilization, the delivery on FY26 guidance remains uncertain. Covenant headroom is narrow: leverage at 3.64x versus a 3.90x ceiling through September 2026, and interest coverage at 1.81x versus a 1.75x minimum. A miss in Q1 could pressure the stock toward the bear-case value of $3.20, while confirmation of recovery would validate management's execution but still leave limited upside until leverage declines. The prudent approach is to wait for 2Q26 KPI data in July to see if Mexico volumes inflect before committing capital.

Thesis delta

The overall thesis remains unchanged: AUNA is a leveraged turnaround play dependent on Mexico recovery, and the Q1 preview does not alter the wait-and-see stance. The article reinforces the DeepValue report's caution by highlighting flat EPS and continued Mexico weakness, suggesting that near-term catalysts are insufficient to upgrade the rating. Any positive surprise in Q1 could provide a tactical entry, but the structural risks from covenant constraints and Mexico utilization persist.